Priority Review in China for Pharnext's PXT3003

Pharnext S.A.S. (Euronext:ALPHA) said China's State Drug Administration granted Priority Review to an NDA for PXT3003 to treat Charcot-Marie-Tooth 1A (CMT1A) disease.

GeneNet Co. Ltd. (Tianjin, China), a joint venture between Pharnext and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), submitted the NDA in December 2017. The JV has commercialization rights to PXT3003 to treat CMT1A in China, including Hong Kong and Macau, and Taiwan (see BioCentury Extra, May 10, 2017)...